Author/Authors :
Asghari Vostakolaei, Mehdi Drug Applied Research Center - Tabriz University of Medical Sciences, Tabriz, Iran , Abdolalizadeh, Jalal Drug Applied Research Center - Tabriz University of Medical Sciences, Tabriz, Iran , Hejazi, Mohammad Saeid Department of Pharmaceutical Biotechnology - Faculty of pharmacy - Tabriz University of Medical Sciences, Tabriz, Iran , Kordi, Shirafkan Department of Medical Biotechnology - Faculty of Advanced Medical Sciences - Tabriz University of Medical Sciences, Tabriz, Iran , Molavi, Ommoleila Department of Pharmaceutical Biotechnology - Faculty of pharmacy - Tabriz University of Medical Sciences, Tabriz, Iran
Abstract :
Heat shock protein 70.1 (Hsp70.1), also known as Hsp70, is a highly conserved member
of the heat shock protein family that exists in all living organisms and determines the protein
fate as molecular chaperones.
Hsp70 basal expression is undetectable or low in most unstressed normal cells, however,
its abundant presence in several types of human cancer cells is reported. Several studies
support upregulated Hsp70 involved in tumor progression and drug resistance through
modulation of cell death pathways and suppresses anticancer immune responses. However,
numerous studies have confirmed that Hsp70 can also induce anticancer immune responses
through the activation of immune cells in particular antigen-presenting cells (APCs).
Regarding the significant and the promising role of vaccines in cancer immunotherapy,
identification and characterization of the overexpressed Hsp70 as a potential immune
stimulatory factor can pave the path for development of highly effective anticancer vaccines.
In this review, we will discuss the interactions of Hsp70 with components of the immune
system in cancers as well as possible strategies to harness Hsp70 for eliciting anticancer
immune responses.
Keywords :
Tumor microenvironment , Single-chain variable fragment antibody , Heat shock protein 70 (Hsp70) , Cancer vaccines , Apoptosis